AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06233630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution iPACK+ACB
Description: ultrasound guided iPACK block + Adductor Canal Block
Study NCT05714241 — intervention group
Intervention type: OTHER
Intervention: Data extraction
Description: After routine coronary function testing using a diagnostic pressure-temperature sensor guidewire in order to assess Coronary Flow Reserve (CFR) and the Index of Microvascular Resistance (IMR); and/or the acetylcholine (Ach) provocative test to assess the presence of coronary vasomotion disorders, patients will be stratified, accordingly to coronary function testing and Ach provocative test, in four groups/endotypes:~1. MVA (evidence of CMD defined as any of abnormal CFR \[\<2.0\], IMR \[≥25\], or microvascular spasm);~2. VSA (CFR ≥2.0, IMR \<25 and epicardial spasm);~3. both MVA and VSA (evidence of CMD and epicardial spasm);~4. none/non-cardiac chest pain (CFR ≥2.0 and IMR \<25 and neither microvascular nor epicardial spasm).
Study NCT05714241 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: At the time of this coronary angiography, arterial blood samples through the radial sheath will be collected. If collected at the time of any follow-up visit, venous blood samples will be collected by venipuncture with the same modalities to obtain whole blood, serum and plasma samples after centrifugation.
Study NCT05714241 — intervention group
Intervention type: OTHER
Intervention: Clinical Follow-up
Description: All patients will undergo a final follow-up visit at 12 months from the date of enrollment.~During the visit, the incidence of MACE in the past months will be investigated, the Seattle Angina Questionnaire (SAQ) will be administered and the SAQ summary score will be collected.
Study NCT05913817 — intervention group
Intervention type: BIOLOGICAL
Intervention: AVT02 (Alvotech Biosimilar to Adalimumab)
Description: Phase IV Study
Study NCT05685550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toposide capsules combined with anrotinib and Emvolizumab group
Description: Elderly patients with extensive SCLC were given etoposide capsules 100mg PO qd\*7d and Envollizumab 300mg/ time IH Q3W in combination with anrotinib 12mg PO qd\*14d,every 21 days until disease progression or adverse reactions that were tolerated.
Study NCT04584086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 3 tesla
Description: 1.5 Tesla MRIs, usually used as pre-treatment and, between 3 and 6 months after irradiation, are replaced in the study by 3 Tesla MRIs (pre-treatment and at 6 months)~In addition, two additional MRIs, also performed with a 3 Tesla magnetic field, will be performed:~* During treatment when half of the prescribed dose has been delivered.~* 1 month after the end of the irradiation.
Study NCT06298890 — intervention group
Intervention type: DEVICE
Intervention: Artificial tears (sodium hyaluronate 0.2%)
Description: Patients randomised into Ist study group will use artificial tears 7 days before the cataract surgery 4 times a day and they will continue to use them after surgery for 3 months.
Study NCT05215990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive metformin with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
Study NCT05215990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive placebo drug with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
Study NCT05210231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: The direct electric current will be applied through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For anodal polarity stimulation over the left TC, the anodal electrode will be placed over the scalp on the T3 area located at 40% of the distance on the left from the Cz point. The cathode electrode will be placed over the contralateral supraorbital area (Fp2). Thereafter, a constant electric current of 2 mA will be applied for 20 min.
Study NCT05210231 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The direct electric current will be applied through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For anodal polarity stimulation over the left TC, the anodal electrode will be placed over the scalp on the T3 area located at 40% of the distance on the left from the Cz point. The cathode electrode will be placed over the contralateral supraorbital area (Fp2). Thereafter, a constant electric current of 2 mA will be applied for 20 min.
Study NCT04890431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: oxygen treatment (5 L/minute for 30 minutes by nasal cannula, twice/day)
Study NCT04890431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ambient air not enriched with oxygen (5 L/minute for 30 minutes by nasal cannula, twice/day)
Study NCT06008028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1015
Description: One tablet administered alone
Study NCT06008028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1015-1
Description: One tablet administered alone
Study NCT06008028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1015-2
Description: One tablet administered alone
Study NCT05562622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel spectacle lens design
Description: Use of lenses may reduce the rate of progression of juvenile myopia
Study NCT05562622 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spectacle lenses
Description: Use of lenses may reduce the rate of progression of juvenile myopia
Study NCT06048848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono-guided injection
Description: After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
Study NCT06048848 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sono-guided injection
Description: After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
Study NCT06048848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
Study NCT06048848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
Study NCT06217276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle fatigue protocol
Description: It will be performed using a powerbreath device at 60% of the maximum inspiratory pressure (MIP) amount obtained by measuring mouth pressure. The protocol includes 7 sets consisting of 2 minutes of inspiratory effort and 1 minute of rest. To further confirm the occurrence of fatigue, the patient will score fatigue using the modified Borg scale, and the score will be 5 or above11. During the application, heart rate, blood pressure and peripheral oxygen saturation will be monitored. The measurement will be performed once for each case.
Study NCT05263505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 MG [Olumiant]
Description: Two tabs daily
Study NCT05263505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Target dose: 20mg weekly
Study NCT05263505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Target dose: 2mg/kg daily
Study NCT05263505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate
Description: Target Dose: 1g twice daily
Study NCT06099015 — intervention group
Intervention type: DEVICE
Intervention: Cera™ Vascular Plug System
Description: The Cera™ Vascular Plug System is composed of Cera™ Vascular Plug and its accessory Introducer Kit. The Cera™ Vascular Plug is a self-expandable, cylindrical Ni-Ti wire mesh device.
Study NCT06359431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel Smart Speculum
Description: The examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately.
Study NCT05421195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids therapy
Description: Oral corticosteroids
Study NCT05421195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory training
Description: repeat and deliberate sniffing of a set of odorants
Study NCT05421195 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Olfactory training
Description: repeat and deliberate sniffing of a set of odorants
Study NCT05046951 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Should I Screen website
Description: The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.
Study NCT05046951 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Should I Screen print booklet
Description: The Should I Screen print-based education will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.
Study NCT06359431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard speculum
Description: he examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately.
Study NCT05266716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Methamphetamine Treatment Program
Description: Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine (TM) with clinical personnel and group therapy, and referral to psychiatrist for medication support, as needed. The program incrementally builds skills and beliefs to develop personally meaningful strategies to combat cravings, using such techniques as regular app-promoted deep breathing exercises, daily exercise, and help in making and sticking to a relapse prevention plan. Counseling sessions are arranged via text sent by the Team Care advocate and also presented to the participant via the app as a reminder. Individual and group therapy sessions occur over Zoom, which is integrated into the app.~Contingency Management (CM). CM utilizes monetary incentives and rewards to promote behavior change.
Study NCT05869916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological first aid
Description: The effect of psychological first aid on earthquake victims was measured using the resilience scale and the secondary traumatic stress scale.
Study NCT05044273 — intervention group
Intervention type: DEVICE
Intervention: Synergy XD stent or Synergy Megatron™ Stent
Description: Percutaneous coronary intervention with Synergy XD stent or Synergy Megatron™ Stent
Study NCT06645678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Elranatamab: Participants will receive SC administration of elranatamab QW or Q2W. The initial doses of elranatamab will be 12mg (C0D1), 32mg (C0D4), and 76mg (C0D8) and will serve as the 2 step-up priming regimen (Cycle 0). Then, 76mg weekly C1-C6 > then 76mg bi-weekly from C7 for those achieving PR or better > then 76mg q4weeks from C12 for those achieving CR or better response. If the participant subsequently begins to have an increase of disease burden not yet qualifying as PD according to IMWG criteria, dose intervals will return to weekly dosing.~premedication for Elranatamab: Acetaminophen 650mg (or paracetamol 500mg), Diphenhydramine 25mg (or equivalent), Dexamethasone 20mg (or equivalent).~In case of mezigdomide discontinuation due to reasons other than disease progression, elranatamab continuation +/- dexamethasone will be allowed until loss of response. The administration of elranatamab +/- dexamethasone will continue per study protocol schedule.
Study NCT06645678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: The first day of study treatment dosing with mezigdomide is considered Day 1 of a cycle. (per recommended phase 2 dose, daily \[qd\], D1-21, q 4weeks). Capsules of mezigdomide will be taken by mouth with or without food.~In case of elranatamab discontinuation due to reasons other than disease progression, mezigdomide continuation +/- dexamethasone will be allowed until loss of response. The administration of mezigdomide will continue per study protocol.
Study NCT06645678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered at the dose of 20 mg/day from C1-3, then 10mg/day from C4-6 as a premedication for elranatamab.~(for those >=75 yrs, with uncontrolled diabetes mellitus, history of intolerance: 10mg/day -> 5mg/day)
Study NCT05182476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study NCT05182476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luvadaxistat
Description: Oral tablets
Study NCT06520670 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary galectin-3 binding protein
Description: Investigate urinary galectin-3 binding protein (G3BP) as a biomarker for lupus nephritis and indicator for disease activity.
Study NCT04990336 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dachaihu decoction compound
Description: Dachaihu decoction compound includes Bupleurum, Rhubarb, Citrus aurantium, Scutellaria, Pinellia, White Peony, Jujube, Ginger.
Study NCT04990336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhubarb single medicine
Description: Rhubarb single medicine
Study NCT04990336 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regular therapies
Description: Regular therapies, such as fluid therapy, for acute pancreatitis
Study NCT04990336 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Regular therapies
Description: Regular therapies, such as fluid therapy, for acute pancreatitis
Study NCT05836012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIL-214
Description: 2 injections - given at 4 months and the second at 6 months of age.
Study NCT05836012 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 injections - given at 4 months and the second at 6 months of age.
Study NCT04990336 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Regular therapies
Description: Regular therapies, such as fluid therapy, for acute pancreatitis
Study NCT05221827 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: C2i Test
Description: The C2i-Test, a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS)-based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD).
Study NCT06484673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan Dispersible Tablets
Description: 1 tablet of 32 mg Bosentan
Study NCT06484673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan Dispersible Tablets
Description: 1 tablet of 32 mg Bosentan
Study NCT06484673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tracleer Tablet for Oral Suspension
Description: 1 tablet of 32 mg Bosentan
Study NCT06484673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tracleer Tablet for Oral Suspension
Description: 1 tablet of 32 mg Bosentan
Study NCT05664113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT)
Description: FMT Lower Delivery Microbiota Preparation, Dose: 250 mL of Microbiota Preparation Material and Route of administration: colonoscopy FMT Upper Delivery Microbiota Preparation, Dose: 60 mL of Microbiota Preparation Material and Route of administration: Naso-enteral tube
Study NCT05578703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty
Description: Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
Study NCT05578703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fundic Mucosal Ablation with ERBE HybridAPC
Description: Fundic mucosal ablation utilizing approved ERBE HybridAPC
Study NCT04677361 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MILs™ in Combination with Pembrolizumab
Description: Efficacy and Safety of MILs™ in Combination with Pembrolizumab in Patients with NSCLC and SCLC
Study NCT05578703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo ESG
Description: Using only Apollo ESG as approved per label
Study NCT05916430 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EarliPoint Investigational Device
Description: Infants will complete eye-tracking data collection at the age of 9 months on the EarliPoint Investigational Device. Eye-tracking video cameras will safely measure the movements of the child's eyes while they watch age-appropriate video scenes of other children playing together. Parents/Caregivers will complete screening forms and questionnaires about their baby's health and development. Parents/caregivers will complete surveys about their child's development. The surveys will be emailed, to be completed when the child is approximately 9, 12, 15, 18, 21, and 24 months old. If the child shows signs of developmental delay, the child will be asked to participate in a comprehensive developmental and diagnostic assessment.
Study NCT06560619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MENTOR
Description: Participants will attend a group-based, 8-week online program (a total of 40 hours) via Zoom videoconferencing. The program is split into three wellness sections (Mindfulness, Exercise, and Nutrition) and eight other sections (self-care skills, core values, outdoor time in nature, rest/relaxation, contribution to others, arts and leisure, relationships, and spiritual practice). Participants will access all assessment and intervention tools on any mobile device (phone, tablet, laptop, desktop) using a password-protected identification (ID) to log in via their devices. Health coaches can create intake flows to collect health data and track analytics. Participants can see their goals, upcoming intervention sessions, and activities through the study application (app). Features of the study app include goal setting, where participants record their goals, zoom videoconferencing links for online classes and coaching sessions, and the ability to share materials with participants.
Study NCT04128774 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone
Description: The case group receives dexamethasone based on the clinical indication.